Labelling/packaging exemption: Bayer aspirin protect

10 March 2006

THERAPEUTIC GOODS ACT 1989

I, PIO CESARIN, Director, Non-Prescription Medicines Branch, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of section 42 DK (1) of the Therapeutic Goods Act, give notice that the restricted representation described in paragraph (a) below, being a representation that is necessary for the appropriate use of the therapeutic goods described in paragraph (b) below, may be included either on the label of the package of those goods or in information included in the package in which those goods are contained:

1. a representation to the effect that the goods described in paragraph (b) below may be used "for the treatment of patients with known cardiovascular or cerebrovascular disease as an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke).";
2. BAYER ASPIRIN PROTECT 100mg tablet blister pack;
   supplied as an over-the-counter drug by Bayer Australia Limited

Dated this 10th day of March 2006

PIO CESARIN
Delegate of the Secretary to the Department of Health and Ageing